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From the beginnings of the War on Cancer, 
officially inaugurated in the early seven-
ties by Richard Nixon, research priorities 
to identify and attack the main weaknesses 
of tumor cells have evolved, following the 
rhythm of technology. From the use of 
overtly toxic and undiscriminating drugs 
to the detailed annotation of cancers on 
a patient-to-patient basis through the use 
of “Omics” approaches, research has strug-
gled in the search for a cure. Is current basic 
research having a more immediate impact 
on nurturing clinical work? Here we discuss 
the recent contributions of basic research 
to prostate cancer therapy, and the factors 
contributing to a change in the way we fight 
this disease, with a focus on hormone sign-
aling and metabolism.
Prostate cancer is the fifth cause of 
death by cancer worldwide (data retrieved 
from the WHO), second in the male pop-
ulation. Prostate cancer arises from the 
aberrant proliferation of epithelial cells, 
termed prostate intraepithelial neopla-
sia (PIN). Cancer cells can further alter 
the structure of the gland, leading to the 
disruption of the basal cell layer and loss 
of basement membrane integrity and the 
onset of invasive prostate cancer lesions. 
Upon sustained hormone-ablation ther-
apy, invasive prostate cancer frequently 
acquires castration-resistant features and 
gains metastatic potential, which accounts 
for a large fraction of morbidity (Moul and 
Dawson, 2012). Much of the effort dedi-
cated to prostate cancer research has been 
oriented at developing efficient therapies 
for the most deadly form of the disease, cas-
tration-resistant prostate cancer (CRPC), 
which often exhibits aberrant production 
of androgens or activating mutations in the 
Androgen Receptor (AR) gene, together with 
inactivating mutations in genes such as the 
tumor suppressor PTEN (Friedlander et al., 
2012). Recent studies indicate that inhibi-
tors of androgen synthesis (CYP17) and AR 
signaling exhibit antitumoral activity in 
CRPC patients. Thus, compounds target-
ing the androgen pathway have emerged as 
leading anticancer agents. CYP17 exhibits 
both 17,20 lyase and 17-hydrolase activity. 
Whereas the 17,20 lyase activity of CYP17 
is involved in androgen synthesis, the 
17-hydrolase activity is relevant for gluco-
corticoid synthesis. Therefore, inhibition of 
both CYP17 activities results in the reduc-
tion of both androgen and glucocorticoid 
synthesis, which has led to the need of 
combining CYP17 inhibitors ith glucocor-
ticoid supplementation, in order to avoid 
undesirable side effects (Attard et al., 2012). 
The US FDA recently approved the CYP17 
inhibitor abiraterone acetate (Zytiga) for 
the treatment of CRPC (De Bono et al., 
2011). In addition, there are inhibitors 
targeting the 17,20 lyase activity of CYP17 
(rather than the 17-hydrolase activity, 
hence eliminating the need for glucocorti-
coid supplementation), such as TAK700, in 
Phase III clinical trials
1 (refs. NCT01193244 
and NCT01193257) and galeterone, a dual 
CYP17/AR inhibitor in Phase I (see text 
footnote 1 ref. NCT00959959), that could 
be adopted as first line therapies for CRPC 
in the near future.
To date, targeting androgen signaling 
in CRPC appears to be one of the most 
attractive approaches, due to the fact that 
resistance to castration is often associated to 
extra-gonadal androgen synthesis (adrenal 
glands, intracrine de novo synthesis) that 
can be targeted with these new pharma-
cological inhibitors (Attard et al., 2012). 
However, these exciting new drugs might 
still fail to function upon the emergence 
of resistant cancer cells (Mostaghel et al., 
2011). Therefore, and in line with the notion 
that single anticancer therapy will only be 
an efficient anticancer approach in a hand-
ful of cancers with a clear oncogene addic-
tion (Weinstein, 2008; Weinstein and Joe, 
2008), the question arises: what will be the 
best drug combination to cure prostate can-
cer? Genetically engineered mouse models 
provide us with a fantastic opportunity to 
study and understand the biological altera-
tions that occur in the disease, and in turn 
might facilitate predicting the best pharma-
cological combination on the basis of the 
genetic make-up of the cancer.
The tumor suppressor PTEN is among 
the most mutated/inactivated genes in pros-
tate cancer, with up to 70% of tumors har-
boring partial or complete loss of PTEN at 
presentation (Salmena et al., 2008). While 
PTEN frequently undergoes loss of het-
erozygosity, it is mostly in advanced can-
cers that complete loss is observed. On this 
basis, a genetic mouse model driven by 
prostate epithelium-specific loss of Pten 
was anticipated to be a faithful model for 
this disease. Indeed, Pten heterozygous mice 
present PIN lesions in the prostate with 
long latency (Di Cristofano et al., 1998; 
Trotman et al., 2003), whereas complete loss 
of PTEN in the prostate epithelium results 
in full-penetrance PIN in early stages, and 
invasive cancer later on, once the underly-
ing senescence response has been evaded 
(Chen et al., 2005; Alimonti et al., 2010). 
This mouse model therefore offers two 
flavors of prostate cancer, onset and pro-
gression, which is extremely useful both for 
biological understanding and therapeutic 
initiatives. Indeed, this model has led to the 
characterization of the intimate association 
between the PI3K pathway and androgen 
signaling in prostate cancer, with recipro-
cal feedback loops triggering compensatory 
activation of these pathways when pharma-
cological inhibitors are employed (Carver 
et al., 2011; Mulholland et al., 2011). The 
idea that emanates from these studies is 
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tures for stemness and p53 and PTEN inac-
tivation), one intermediate (characterized 
by the TMPRSS2–ERG fusion) and three 
benign. Since this classification was found 
to be independent of Gleason score, it may 
help to predict poor outcome in patients.
With all the new technology available 
and the knowledge we have acquired in the 
last decade, it becomes clear that evaluat-
ing the metabolic alterations occurring at 
different stages of prostate cancer could 
offer new biomarkers as well as targets 
for therapy, which, in combination with 
the aforementioned approaches, could 
become a game changer in the diagnosis 
and treatment of this disease. The relation-
ship between obesity and cancer is, at least 
in part, largely dependent the effects of 
obesity on metabolic tissues such as alter-
ations in hormone/cytokine homeostasis 
(Khandekar et al., 2011). On the one hand, 
excessive lipid accumulation in the adipose 
tissue modifies its function, resulting in the 
secretion of pro-inflammatory cytokines 
(i.e., TNF-alpha and IL-6), the production 
of leptin (which has been closely associ-
ated to prostate cancer incidence) and 
reduced levels of adiponectin, which has 
anticancer properties, among other things. 
On the other hand, obesity and metabolic 
disorders can alter the function of the 
inflammatory system and the production 
of other hormones, which could have a 
critical effect on neoplastic cells, such as 
IGF-1. The metabolic component of pros-
tate cancer leads us to another question: 
Is the association between prostate cancer 
occurrence and metabolic diseases, such 
as obesity, a reflection of more than just 
a non-cell autonomous, systemic altera-
tion of cancer-promoting factors? Prostate 
cancer is among the types of tumor that 
are directly correlated with obesity (Wolin 
et al., 2010). Moreover, a healthy diet and 
moderate physical activity in prostate can-
cer patients subjected to prostatectomy is 
associated with increased survival (Davies 
et al., 2011). This concept is particularly 
important given that prostate cancer is 
more frequent in men of advanced age, 
who have a higher incidence of obesity. A 
local study that included this type of analy-
sis
2 (Vital study 2005; N = 4220) showed 
dependence on mTOR signaling (Clegg 
et al., 2011). These data further enforce the 
notion that targeting Myc in cancer would 
be of high therapeutic interest, and further 
studies will determine whether targeting 
Myc signaling (since Myc protein is largely 
undruggable) could have a therapeutic ben-
efit in this type of cancer.
During the last couple of years, several 
independent groups have found evidence 
for a connection between the reprogram-
ming of cellular metabolism and androgen 
signaling. This is particularly interesting, as 
metabolic reprogramming appears to take 
place in all cancer cells, and so represents an 
attractive target for therapy (Vander Heiden 
et al., 2009). On the one hand, androgen 
signaling promotes a Ca2+/Calmodulin-
dependent protein kinase kinase beta 
(CaMKKβ)-orchestrated metabolic switch, 
with increased anabolism and the Warburg 
effect, characterized by increased glucose 
uptake and lactate production (Massie et al., 
2011). On the other hand, metabolomic 
analysis of androgen-dependent and -inde-
pendent PCa cell lines has unraveled core 
differences in cellular metabolism related to 
androgen signaling (Putluri et al., 2011). In 
addition, metabolomic studies have allowed 
not only a better understanding of biological 
processes, but also potential biomarkers for 
the progression of the disease (Sreekumar 
et al., 2009), although we are clearly only at 
the beginning of an obscure and complex 
path (Colleselli et al., 2010; Hewavitharana, 
2010; Jentzmik et al., 2010, 2011).
Omics, when used wisely, are a definitive 
source of information for the identification 
of biomarkers and the definition of molecu-
lar subtypes in cancer. This has been beau-
tifully exemplified in breast cancer, where 
transcriptional gene expression profiles 
have led to the definition of clinically and 
therapeutically relevant molecular subtypes 
(Perou et al., 2000; Wang et al., 2004; Matros 
et al., 2005; Desmedt et al., 2008), or to the 
definition of signatures of good and poor 
prognosis (Van ‘t Veer et al., 2002). A simi-
lar effort has been made for prostate can-
cer, although a clearly defined portrait of 
molecular subtypes has not yet emerged. A 
recent study (Markert et al., 2011) classified 
tumors on the basis of mRNA microarray 
signature profiles for stemness, inactivation 
of tumor suppressors, and activation of 
oncogenic pathways. This led to the identi-
fication of five tumor subsets, one with very 
that the best response in patients might be 
achieved by combined inhibition of PI3K 
and AR signaling.
The use of mouse models, has also led 
to a better understanding of the biologi-
cal contribution of genetic alterations to 
prostate cancer pathogenesis. In this con-
text, it is worth mentioning the case of a 
genetic alteration that has provided a new 
view of the contribution of androgen sign-
aling to prostate cancer, and also changed 
the dogma about chromosomal rearrange-
ments in solid tumors. It was originally 
thought that chromosomal translocations, 
while frequently observed in hematological 
malignancies and sarcomas, were extremely 
rare in solid tumors. However, Chinnaiyan’s 
group described that a single translocation 
could be observed in up to 50% of prostate 
cancers. This translocation involved the 
androgen-regulated promoter of trans-
membrane protease, serine 2 (TMPRSS2) 
and an ETS-related protein (ERG). This 
observation may be key to understanding 
how androgenic signals rewire cell sign-
aling and the transcriptional landscape. 
Importantly, mouse modeling was argu-
ably key to a better understanding of the 
contribution of this genetic alteration to 
the disease. Transgenic mice in which ERG 
is placed under the control of androgens 
(such as TMPRS22 or Probasin promoter) 
develop invasive cancer, but only in the 
context of PI3-kinase pathway activation 
(Carver et al., 2009b; King et al., 2009). The 
study of these mice indicated that while ERG 
over-expression was not sufficient to initi-
ate prostate cancer (Carver et al., 2009a), it 
would result in an invasive phenotype when 
one allele of PTEN was missing.
In addition to PTEN and ERG, c-Myc is 
found mutated or over-expressed in a large 
fraction of prostate cancers (Jenkins et al., 
1997; Qian et al., 1997). In line with this 
notion, mice over-expressing c-Myc develop 
PIN followed by progression to invasive can-
cer, and exhibit genetic and histological fea-
tures reminiscent of human prostate cancer 
(Ellwood-Yen et al., 2003). Moreover, these 
two key oncogenic pathways (PTEN-PI3K-
AKT and c-Myc) cooperate in the develop-
ment and progression of prostate cancer. 
The group of Sawyers recently showed that 
crossing Pb-Myr-AKT1 and Pb-Myc trans-
genic mice led to a dramatic acceleration 
of invasive prostate adenocarcinoma onset 
with inflammatory features and a reduced 
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an obesity incidence of nearly 20% of 
men > 60 years old (6% higher than in the 
overall population, 2.6 times more than in 
the population of 18–40 year-olds). These 
data suggest that BMI and the incidence of 
obesity tend to be higher in the elderly pop-
ulation. An independent study carried out 
at Basurto Hospital (Bilbao) in 2010 among 
prostate cancer patients revealed that a 
high percentage of men (28%) diagnosed 
with prostate cancer presented with a BMI 
>30 (average age 68; average BMI = 28.04; 
N = 140), classified as obesity. These data in 
turn suggest that the population suffering 
from prostate cancer might exhibit a differ-
ent (higher) incidence of obesity compared 
to other types of cancer that are detected 
across a wider range of age. In addition, it 
calls for a careful evaluation of the particu-
lar features and characteristics of prostate 
cancer in obese patients, as they may repre-
sent a clinical sub-group with a differential 
response to therapy.
In conclusion, the pathogenesis of pros-
tate cancer involves an array of genetic and 
environmental factors, with an intimate 
relationship between signaling cascades, 
metabolic pathways, and hormone signal-
ing. The current mouse models of prostate 
cancer have proven to be extremely useful 
to define both the biological basis of the 
disease and to predict therapeutic efficacy. 
However, more detailed studies are needed 
in order to define potential prostate cancer 
subpopulations, and this should be possible 
through the integration of new biomarkers, 
studies of the nutritional habits of patients, 
and the prevalent mutations.
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